These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 38417085

  • 21. T-cell posttransplant lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.
    Kuno M, Ito A, Maeshima AM, Taniguchi H, Tanaka T, Inamoto Y, Kurosawa S, Kim SW, Fukuda T.
    Int J Hematol; 2020 Aug; 112(2):193-199. PubMed ID: 32472530
    [Abstract] [Full Text] [Related]

  • 22. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience.
    Kogan-Liberman D, Burroughs M, Emre S, Moscona A, Shneider BL.
    J Pediatr Gastroenterol Nutr; 2001 Oct; 33(4):445-9. PubMed ID: 11698761
    [Abstract] [Full Text] [Related]

  • 23. The Role of Antiviral Prophylaxis for the Prevention of Epstein-Barr Virus-Associated Posttransplant Lymphoproliferative Disease in Solid Organ Transplant Recipients: A Systematic Review.
    AlDabbagh MA, Gitman MR, Kumar D, Humar A, Rotstein C, Husain S.
    Am J Transplant; 2017 Mar; 17(3):770-781. PubMed ID: 27545492
    [Abstract] [Full Text] [Related]

  • 24. Epstein-Barr virus posttransplant lymphoproliferative disorder: update on management and outcomes.
    Lindsay J, Othman J, Heldman MR, Slavin MA.
    Curr Opin Infect Dis; 2021 Dec 01; 34(6):635-645. PubMed ID: 34751183
    [Abstract] [Full Text] [Related]

  • 25. Post-transplant lymphoproliferative disorder in pediatric liver transplant recipients: Experience from a South African transplant center.
    Walabh P, Moore DP, Hajinicolaou C.
    Transpl Infect Dis; 2024 Apr 01; 26(2):e14221. PubMed ID: 38152054
    [Abstract] [Full Text] [Related]

  • 26. Comparative analysis of tabelecleucel and current treatment in patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease following hematopoietic cell transplant or solid organ transplant.
    Barlev A, Zimmermann H, Guzman-Becerra N, Mehta A, Xing B, Macabeo B, Thivolet M, Brookhart MA.
    J Med Econ; 2024 Apr 01; 27(1):789-795. PubMed ID: 38727527
    [Abstract] [Full Text] [Related]

  • 27. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients.
    Colombini E, Guzzo I, Morolli F, Longo G, Russo C, Lombardi A, Merli P, Barzon L, Murer L, Piga S, Ciofi Degli Atti ML, Locatelli F, Dello Strologo L.
    Pediatr Nephrol; 2017 Aug 01; 32(8):1433-1442. PubMed ID: 28280938
    [Abstract] [Full Text] [Related]

  • 28. Epstein-Barr virus load in transplant patients: Early detection of post-transplant lymphoproliferative disorders.
    Fellner MD, Durand KA, Solernou V, Bosaleh A, Balbarrey Z, García de Dávila MT, Rodríguez M, Irazu L, Alonio LV, Picconi MA.
    Rev Argent Microbiol; 2016 Aug 01; 48(2):110-8. PubMed ID: 27157146
    [Abstract] [Full Text] [Related]

  • 29. Clinical and virologic outcomes in high-risk adult Epstein-Barr virus mismatched organ transplant recipients.
    Kumar D, Patil N, Husain S, Chaparro C, Bhat M, Kim SJ, Humar A.
    Clin Transplant; 2017 Jul 01; 31(7):. PubMed ID: 28489256
    [Abstract] [Full Text] [Related]

  • 30. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients.
    Riddler SA, Breinig MC, McKnight JL.
    Blood; 1994 Aug 01; 84(3):972-84. PubMed ID: 8043879
    [Abstract] [Full Text] [Related]

  • 31. Impact of prophylaxis with rituximab on EBV-related complications after allogeneic hematopoietic cell transplantation in children.
    Marjańska A, Pogorzała M, Dziedzic M, Czyżewski K, Richert-Przygońska M, Dębski R, Bogiel T, Styczyński J.
    Front Immunol; 2024 Aug 01; 15():1427637. PubMed ID: 39055711
    [Abstract] [Full Text] [Related]

  • 32. Epstein-Barr virus-associated post-transplantation lymphoproliferative disorder: potential treatments and implications for nursing practice.
    Jiménez S.
    Clin J Oncol Nurs; 2015 Feb 01; 19(1):94-8. PubMed ID: 25689655
    [Abstract] [Full Text] [Related]

  • 33. Expert Consensus on the Characteristics of Patients with Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) for Whom Standard-Dose Chemotherapy May be Inappropriate: A Modified Delphi Study.
    Chaganti S, Barlev A, Caillard S, Choquet S, Cwynarski K, Friedetzky A, González-Barca E, Sadetsky N, Schneeberger S, Thirumalai D, Zinzani PL, Trappe RU.
    Adv Ther; 2023 Mar 01; 40(3):1267-1281. PubMed ID: 36681739
    [Abstract] [Full Text] [Related]

  • 34. Management of post-transplant Epstein-Barr virus-related lymphoproliferative disease in solid organ and hematopoietic stem cell recipients.
    Marques HH, Shikanai-Yasuda MA, dAzevedo LS, Caiaffa-Filho HH, Pierrotti LC, Aquino MZ, Lopes MH, Maluf NZ, Campos SV, Costa SF.
    Rev Soc Bras Med Trop; 2014 Mar 01; 47(5):543-6. PubMed ID: 25467252
    [Abstract] [Full Text] [Related]

  • 35. Dynamics of Epstein-Barr virus on post-transplant lymphoproliferative disorders after antithymocyte globulin-conditioned allogeneic hematopoietic cell transplant.
    Lindsay J, Othman J, Yong MK, Ritchie D, Chee L, Tay K, Tio SY, Kerridge I, Fay K, Stevenson W, Arthur C, Chen SC, Kong DCM, Greenwood M, Pergam SA, Liu C, Slavin MA.
    Transpl Infect Dis; 2021 Oct 01; 23(5):e13719. PubMed ID: 34453768
    [Abstract] [Full Text] [Related]

  • 36. Evidence of Epstein-Barr virus heterogeneous gene expression in adult lung transplant recipients with posttransplant lymphoproliferative disorder.
    Zaffiri L, Frankel C, Bush EJ, Neely ML, Pavlisko EN, Mokrova IL, Luftig MA, Palmer SM.
    J Med Virol; 2021 Aug 01; 93(8):5040-5047. PubMed ID: 33704812
    [Abstract] [Full Text] [Related]

  • 37. Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation.
    Kalra A, Roessner C, Jupp J, Williamson T, Tellier R, Chaudhry A, Khan F, Taparia M, Jimenez-Zepeda VH, Stewart DA, Daly A, Storek J.
    Clin Transplant; 2018 Jan 01; 32(1):. PubMed ID: 29114932
    [Abstract] [Full Text] [Related]

  • 38. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting.
    Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G, Habermann TM, Wiesner PH, Swinnen JL, Woodle ES, Bromberg JS.
    Transplantation; 1999 Nov 27; 68(10):1517-25. PubMed ID: 10589949
    [Abstract] [Full Text] [Related]

  • 39. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder.
    Green M, Michaels MG.
    Am J Transplant; 2013 Feb 27; 13 Suppl 3():41-54; quiz 54. PubMed ID: 23347213
    [Abstract] [Full Text] [Related]

  • 40. Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
    Patel C, Pasciolla M, Abramova R, Salerno D, Gomez-Arteaga A, Shore TB, Orfali N, Mayer S, Hsu J, Phillips AA, Chaekal OK, Satlin MJ, Soave R, Kodiyanplakkal RPL, Drelick A, Plate M, Besien KV.
    Transplant Cell Ther; 2023 Feb 27; 29(2):132.e1-132.e5. PubMed ID: 36334653
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.